Jazz Pharmaceuticals plc (JAZZ) shareholders
Close on Nov 17, 2026Market cap $15.63BP/E 78.4Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 5,872,123 | 9.50% | 13G (passive) amendment | Sep 30, 2024 |
| Abigail P. Johnson Joint filing with FMR LLC (8.60%) | 5,601,907 | 8.60% | 13G (passive) amendment | Sep 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (7.40%) | 4,675,459 | 7.40% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 3,103,522 | 5.04% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of JAZZ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,968,603 | 9.19% | $1.44B | +376,903 | 0.02% |
| FMR LLC | 4,609,326 | 7.10% | $1.11B | +2,333,564 | 0.05% |
| Vanguard Portfolio Management LLC | 3,036,213 | 4.68% | $731.64M | +52,971 | 0.03% |
| Vanguard Capital Management LLC | 2,729,650 | 4.20% | $657.76M | +81,317 | 0.01% |
| Capital World Investors | 2,697,610 | 4.16% | $650.04M | +24,234 | 0.08% |
| Lsv Asset Management | 2,275,145 | 3.50% | $548.24M | −111,695 | 0.99% |
| Franklin Resources Inc | 2,040,250 | 3.14% | $491.64M | +81,310 | 0.11% |
| State Street Corp | 1,999,816 | 3.08% | $481.90M | +108,170 | 0.01% |
| Dimensional Fund Advisors LP | 1,713,592 | 2.64% | $412.91M | −181,623 | 0.07% |
| Fuller & Thaler Asset Management, Inc. | 1,638,544 | 2.52% | $394.84M | −37,598 | 1.08% |
| Bank of New York Mellon Corp | 1,578,013 | 2.43% | $380.25M | −101,358 | 0.06% |
| Aqr Capital Management LLC | 1,522,568 | 2.35% | $359.94M | +184,110 | 0.13% |
| Geode Capital Management, LLC | 1,483,031 | 2.28% | $357.44M | +245,414 | 0.02% |
| Ameriprise Financial Inc | 1,215,523 | 1.87% | $292.90M | −392,953 | 0.06% |
| JPMorgan Chase & Co | 1,160,786 | 1.79% | $276.63M | −43,567 | 0.02% |
| Bank Of America Corp /De/ | 1,136,091 | 1.75% | $273.76M | +121,291 | 0.02% |
| Citadel Advisors LLC | 1,006,676 | 1.55% | $242.58M | −252,768 | 0.03% |
| Swedbank AB | 968,092 | 1.49% | $233.28M | −24,016 | 0.20% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 799,297 | 1.23% | $192.61M | −85,904 | 0.19% |
| Millennium Management LLC | 763,880 | 1.18% | $184.07M | −498,631 | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 643 | 64M | 99.2% | 133 / 241 | 188 / 56 | 9M | 10M |
| Q1 2026 | 575 | 65M | 100.0% | 92 / 226 | 163 / 79 | 15M | 7M |
| Q4 2025 | 574 | 63M | 97.7% | 129 / 179 | 195 / 51 | 10M | 10M |
| Q3 2025 | 503 | 63M | 96.5% | 61 / 163 | 200 / 53 | 7M | 6M |
| Q2 2025 | 502 | 62M | 95.8% | 60 / 188 | 179 / 103 | 9M | 6M |
| Q1 2025 | 550 | 59M | 90.9% | 100 / 218 | 157 / 52 | 8M | 7M |
| Q4 2024 | 509 | 59M | 91.2% | 92 / 169 | 173 / 56 | 6M | 6M |
| Q3 2024 | 478 | 59M | 91.4% | 77 / 164 | 159 / 50 | 12M | 6M |
| Q2 2024 | 456 | 59M | 91.0% | 62 / 160 | 165 / 83 | 8M | 10M |
| Q1 2024 | 481 | 61M | 94.5% | 53 / 184 | 160 / 67 | 9M | 7M |
| Q4 2023 | 500 | 59M | 91.4% | 79 / 166 | 179 / 58 | 9M | 6M |
| Q3 2023 | 485 | 57M | 87.2% | 62 / 163 | 178 / 43 | 4M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
209 funds held JAZZ in Q2 2026, 63% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of JAZZ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,892,522 | 2.92% | $456.04M | 0.02% | Jun 30, 2026 |
| Fullerthaler Behavioral Small Cap Equity | 1,561,563 | 2.41% | $376.29M | 2.97% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,366,767 | 2.11% | $329.35M | 0.17% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 865,937 | 1.33% | $208.66M | 0.31% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 719,211 | 1.11% | $173.31M | 0.18% | Jun 30, 2026 |
| VictoryShares Free Cash Flow ETF | 469,858 | 0.72% | $113.22M | 1.46% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 168,574 | 0.26% | $42.63M | 0.28% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 164,206 | 0.25% | $38.83M | 0.20% | May 31, 2026 |
| iShares U.S. Pharmaceuticals ETF | 163,023 | 0.25% | $39.28M | 3.45% | Jun 30, 2026 |
| Avantis U.S. Large Cap Value ETF | 154,718 | 0.24% | $36.59M | 0.28% | May 31, 2026 |
| Pear tree polaris foreign value fund | 150,306 | 0.23% | $36.22M | 2.42% | Jun 30, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 147,012 | 0.23% | $37.17M | 0.08% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 133,819 | 0.21% | $32.25M | 0.27% | Jun 30, 2026 |
| iShares Russell 1000 Value ETF | 133,445 | 0.21% | $32.16M | 0.04% | Jun 30, 2026 |
| Nuveen Mid Cap Value Fund | 127,888 | 0.20% | $32.34M | 1.92% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Renee D. Gala | President & CEO, Director | 140,394 | 0.22% | Nov 5, 2026 |
| Patricia Carr | SVP, Chief Accounting Officer | 6,512 | 0.01% | Nov 6, 2026 |
| Neena M. Patil | EVP & Chief Legal Officer | 47,671 | 0.07% | Sep 14, 2026 |
| Mary Elizabeth Henderson | SVP, Technical Operations | 23,815 | 0.04% | Sep 10, 2026 |
| Robert Iannone | EVP, Global Head of R&D & CMO | 112,107 | 0.17% | Aug 31, 2026 |
| Samantha Pearce | EVP, Chief Commercial Officer | 47,131 | 0.07% | Aug 7, 2026 |
| Philip L. Johnson | EVP & Chief Financial Officer | 56,431 | 0.09% | Jul 2, 2026 |
| Bruce C. Cozadd | Director | 357,567 | 0.55% | Nov 10, 2026 |
| Patrick Kennedy | Director | 8,292 | 0.01% | Sep 2, 2026 |
| Laura Hamill | Director | 8,524 | 0.01% | Sep 2, 2026 |
| Norbert G. Riedel | Director | 17,553 | 0.03% | Sep 2, 2026 |
| Heather Ann McSharry | Director | 18,199 | 0.03% | Sep 2, 2026 |
| Mark Douglas Smith | Director | 9,579 | 0.01% | Sep 2, 2026 |
| Ted W. Love | Director | 2,389 | 0.00% | Sep 2, 2026 |
| Rick E. Winningham | Director | 9,480 | 0.01% | Sep 2, 2026 |
| Patrick G. Enright | Director | 21,278 | 0.03% | Sep 2, 2026 |
| Jennifer E. Cook | Director | 10,736 | 0.02% | Sep 2, 2026 |
| Seamus Mulligan | Director | 1,286,254 | 1.98% | Aug 7, 2026 |
| Kenneth W. O'Keefe | Director | 30,256 | 0.05% | Dec 4, 2025 |
| Anne ORiordan | Director | 16,500 | 0.03% | Aug 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bruce C. Cozadd Director | Nov 6, 2026 | Sale | −5,923 | $237.39 | $1.41M | 357,567 |
| Bruce C. Cozadd Director | Nov 6, 2026 | Sale | −24,483 | $236.84 | $5.80M | 363,490 |
| Bruce C. Cozadd Director | Nov 6, 2026 | Sale | −10,688 | $235.82 | $2.52M | 387,973 |
| Bruce C. Cozadd Director | Nov 6, 2026 | Sale | −27,714 | $234.91 | $6.51M | 398,661 |
| Bruce C. Cozadd Director | Nov 6, 2026 | Option exercise | +85,766 | $136.18 | $11.68M | 426,375 |
| Bruce C. Cozadd Director | Nov 6, 2026 | Option exercise | +734 | $136.18 | $99.96K | 340,609 |
| Patricia Carr SVP, Chief Accounting Officer | Nov 4, 2026 | Sale | −163 | $231.27 | $37.70K | 6,512 |
| Patricia Carr SVP, Chief Accounting Officer | Nov 4, 2026 | Sale | −1,250 | $231.37 | $289.21K | 6,675 |
| Patricia Carr SVP, Chief Accounting Officer | Nov 4, 2026 | Option exercise | +1,250 | $140.03 | $175.04K | 7,925 |
| Renee D. Gala President & CEO, Director | Nov 3, 2026 | Sale(10b5-1 plan) | −1,000 | $225.37 | $225.37K | 140,394 |
| Bruce C. Cozadd Director | Nov 2, 2026 | Sale(10b5-1 plan) | −6,000 | $215.84 | $1.30M | 339,875 |
| Renee D. Gala President & CEO, Director | Oct 6, 2026 | Sale(10b5-1 plan) | −2,000 | $236.40 | $472.80K | 141,394 |
| Bruce C. Cozadd Director | Oct 1, 2026 | Sale(10b5-1 plan) | −6,000 | $230.33 | $1.38M | 345,875 |
| Neena M. Patil EVP & Chief Legal Officer | Sep 10, 2026 | Sale(10b5-1 plan) | −1,200 | $240.94 | $289.13K | 47,671 |
| Mary Elizabeth Henderson SVP, Technical Operations | Sep 8, 2026 | Tax withholding | −15 | $241.20 | $3.62K | 23,815 |
| Mary Elizabeth Henderson SVP, Technical Operations | Sep 8, 2026 | Tax withholding | −1,412 | $243.03 | $343.16K | 23,830 |
| Renee D. Gala President & CEO | Sep 8, 2026 | Sale(10b5-1 plan) | −2,000 | $243.03 | $486.06K | 143,394 |
| Renee D. Gala President & CEO | Sep 8, 2026 | Tax withholding | −1,967 | $246.81 | $485.48K | 145,394 |
| Bruce C. Cozadd Director | Sep 1, 2026 | Sale(10b5-1 plan) | −6,000 | $250.13 | $1.50M | 351,875 |
| Mark Douglas Smith Director | Aug 31, 2026 | Tax withholding | −1,692 | $241.39 | $408.43K | 9,579 |
| Mark Douglas Smith Director | Aug 31, 2026 | Tax withholding | −14 | $244.64 | $3.42K | 11,271 |
| Ted W. Love Director | Aug 31, 2026 | Tax withholding | −737 | $241.39 | $177.90K | 2,389 |
| Ted W. Love Director | Aug 31, 2026 | Tax withholding | −6 | $244.06 | $1.46K | 3,126 |
| Rick E. Winningham Director | Aug 31, 2026 | Tax withholding | −1,692 | $241.39 | $408.43K | 9,480 |
| Rick E. Winningham Director | Aug 31, 2026 | Tax withholding | −14 | $244.64 | $3.42K | 9,466 |
| Mary Elizabeth Henderson SVP, Technical Operations | Aug 31, 2026 | Tax withholding | −16 | $244.64 | $3.91K | 25,242 |
| Mary Elizabeth Henderson SVP, Technical Operations | Aug 31, 2026 | Tax withholding | −2,076 | $241.39 | $501.13K | 25,258 |
| Bruce C. Cozadd Director | Aug 31, 2026 | Tax withholding | −1,209 | $241.39 | $291.84K | 357,875 |
| Bruce C. Cozadd Director | Aug 31, 2026 | Tax withholding | −10 | $244.06 | $2.44K | 359,084 |
| Patrick Kennedy Director | Aug 31, 2026 | Tax withholding | −15 | $244.06 | $3.66K | 8,292 |
| Patrick Kennedy Director | Aug 31, 2026 | Tax withholding | −1,840 | $241.39 | $444.16K | 6,452 |
| Jennifer E. Cook Director | Aug 31, 2026 | Tax withholding | −1,692 | $241.39 | $408.43K | 10,736 |
| Jennifer E. Cook Director | Aug 31, 2026 | Tax withholding | −14 | $244.06 | $3.42K | 12,428 |
| Patrick G. Enright Director | Aug 31, 2026 | Tax withholding | −1,692 | $241.39 | $408.43K | 21,278 |
| Patrick G. Enright Director | Aug 31, 2026 | Tax withholding | −14 | $244.64 | $3.42K | 22,970 |
| Laura Hamill Director | Aug 31, 2026 | Tax withholding | −14 | $244.06 | $3.42K | 8,524 |
| Laura Hamill Director | Aug 31, 2026 | Tax withholding | −1,692 | $241.39 | $408.43K | 6,832 |
| Norbert G. Riedel Director | Aug 31, 2026 | Tax withholding | −1,692 | $241.39 | $408.43K | 6,923 |
| Norbert G. Riedel Director | Aug 31, 2026 | Tax withholding | −14 | $244.64 | $3.42K | 8,615 |
| Heather Ann McSharry Director | Aug 31, 2026 | Tax withholding | −1,840 | $241.39 | $444.16K | 18,199 |
| Heather Ann McSharry Director | Aug 31, 2026 | Tax withholding | −15 | $244.64 | $3.67K | 20,039 |
| Robert Iannone EVP, Global Head of R&D & CMO | Aug 27, 2026 | Option exercise | +884 | $113.10 | $99.98K | 112,107 |
| Robert Iannone EVP, Global Head of R&D & CMO | Aug 27, 2026 | Option exercise | +26,116 | $113.10 | $2.95M | 111,223 |
| Robert Iannone EVP, Global Head of R&D & CMO | Aug 27, 2026 | Sale(10b5-1 plan) | −19,639 | $250.60 | $4.92M | 75,245 |
| Robert Iannone EVP, Global Head of R&D & CMO | Aug 27, 2026 | Sale(10b5-1 plan) | −300 | $252.76 | $75.83K | 65,686 |
| Robert Iannone EVP, Global Head of R&D & CMO | Aug 27, 2026 | Sale(10b5-1 plan) | −9,259 | $251.95 | $2.33M | 65,986 |
| Robert Iannone EVP, Global Head of R&D & CMO | Aug 27, 2026 | Sale(10b5-1 plan) | −18,113 | $250.02 | $4.53M | 94,884 |
| Robert Iannone EVP, Global Head of R&D & CMO | Aug 27, 2026 | Sale(10b5-1 plan) | −11,423 | $248.67 | $2.84M | 112,997 |
| Robert Iannone EVP, Global Head of R&D & CMO | Aug 27, 2026 | Sale(10b5-1 plan) | −18,187 | $247.86 | $4.51M | 124,420 |
| Robert Iannone EVP, Global Head of R&D & CMO | Aug 27, 2026 | Option exercise | +2,916 | $137.12 | $399.84K | 142,607 |
| Robert Iannone EVP, Global Head of R&D & CMO | Aug 27, 2026 | Option exercise | +27,584 | $137.12 | $3.78M | 139,691 |
| Bruce C. Cozadd Director | Aug 5, 2026 | Award | +1,605 | – | – | 362,287 |
| Seamus Mulligan Director | Aug 5, 2026 | Award | +1,605 | – | – | 1,184,633 |
| Mark Douglas Smith Director | Aug 5, 2026 | Award | +1,605 | – | – | 11,285 |
| Heather Ann McSharry Director | Aug 5, 2026 | Award | +1,605 | – | – | 20,054 |
| Norbert G. Riedel Director | Aug 5, 2026 | Award | +1,605 | – | – | 8,629 |
| Laura Hamill Director | Aug 5, 2026 | Award | +1,605 | – | – | 8,538 |
| Patrick Kennedy Director | Aug 5, 2026 | Award | +1,605 | – | – | 8,307 |
| Ted W. Love Director | Aug 5, 2026 | Award | +1,605 | – | – | 3,132 |
| Patrick G. Enright Director | Aug 5, 2026 | Award | +1,605 | – | – | 22,984 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Jazz Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,743 shares on Oct 5, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Bruce C. Cozadd Director | Nov 6, 2026 | 68,808 | $16.24M | Nov 6, 2026 | Stock Option Exercise |
| Patricia Carr Officer | Nov 4, 2026 | 1,413 | $326.91K | Nov 4, 2026 | Stock Option Exercise |
| Renee D. Gala Officer, Director | Nov 3, 2026 | 1,000 | $225.37K | Nov 3, 2026 | Restricted Stock |
| Bruce C. Cozadd Officer | Nov 2, 2026 | 6,000 | $1.30M | Nov 2, 2026 | Stock Option |
| Anne O'Riordan Director | Oct 8, 2026 | 14,687 | $3.36M | Oct 8, 2026 | Stock Option Exercise |
| Renee D. Gala Officer | Oct 6, 2026 | 2,000 | $472.80K | Oct 6, 2026 | Restricted Stock |
| Bruce C. Cozadd Officer | Oct 1, 2026 | 6,000 | $1.38M | Oct 1, 2026 | Stock Option |
| Neena M. Patil Officer | Sep 10, 2026 | 1,200 | $289.13K | Sep 10, 2026 | Restricted Stock |
| Renee D. Gala Officer | Sep 8, 2026 | 2,000 | $486.06K | Sep 8, 2026 | Restricted Stock |
| Mary Elizabeth Henderson Director | Sep 8, 2026 | 2,691 | $664.17K | Sep 8, 2026 | RESTRICTED STOCK VESTING |
| Bruce C. Cozadd Officer | Sep 1, 2026 | 6,000 | $1.50M | Sep 1, 2026 | Stock Option |
| Jennifer E. Cook Director | Aug 31, 2026 | 3,507 | $857.60K | Aug 31, 2026 | RESTRICTED STOCK VESTING |
| Heather Ann McSharry Director | Aug 31, 2026 | 3,507 | $857.60K | Aug 31, 2026 | RESTRICTED STOCK VESTING |
| Bruce C. Cozadd Director | Aug 31, 2026 | 2,506 | $612.82K | Aug 31, 2026 | RESTRICTED STOCK VESTING |
| Ted W. Love Director | Aug 31, 2026 | 1,527 | $373.41K | Aug 31, 2026 | RESTRICTED STOCK VESTING |
See a number that looks wrong?